The story of (cerivastatin) is a cautionary tale of a medical breakthrough that turned into a pharmaceutical crisis, ultimately leading to one of the most significant drug recalls in history. The Rise of a "Blockbuster"
By 2001, the evidence became impossible to ignore. Internal documents later suggested that Bayer may have been aware of these risks as early as the drug's US approval in 1997. On , Bayer voluntarily withdrew Baycol from the global market following reports linking it to 31 deaths in the U.S. and dozens more worldwide. Study: Baycol risks greaterthan believed - NBC News baycol
As Baycol’s popularity grew, so did reports of a rare but devastating side effect: . This condition causes muscle tissue to break down and leak into the bloodstream, which can lead to severe muscle pain, kidney failure, and death. The story of (cerivastatin) is a cautionary tale
Baycol was fast-acting and highly effective at lower doses than its competitors, quickly becoming Bayer's third best-selling drug. By 2001, it was used by nearly 700,000 people in the United States alone. The Hidden Danger On , Bayer voluntarily withdrew Baycol from the
While all statins carry a minor risk of this condition, Baycol’s risk was found to be significantly higher. The danger escalated dramatically when the drug was taken in combination with , another cholesterol medication; in these cases, the risk of muscle destruction was up to 10 times higher than with other statins. The Fall and Recall
In the late 1990s, the pharmaceutical world was in a race to solve a growing global health crisis: high cholesterol. Bayer, the German pharmaceutical giant, introduced Baycol in 1997 as a powerful addition to the "statin" family—a class of drugs designed to block cholesterol production in the liver.